Novartis RNA drug falls short in rare muscle disease study

1 source ·1 article ·Sep 8, 13:23 UTC Atrium Therapeutics Novartis

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·Sep 8, 13:23 UTC

Novartis RNA drug falls short in rare muscle disease study

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

Novartis RNA drug falls short in rare muscle disease study

Novartis RNA drug falls short in rare muscle disease study →

Novartis RNA drug falls short in rare muscle disease study